Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis
ConclusionsCertain DMTs have the potential to positively impact QoL of PwMS, and the assessment and reporting of QoL is suboptimal with a multitude of diverse instruments being used. There is an urgent need that design and reporting of clinical trials reflect the critical importance of QoL for PwMS. (Source: Journal of Neurology)
Source: Journal of Neurology - April 16, 2024 Category: Neurology Source Type: research
Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center
ConclusionATZ is a high efficacy therapy for active MS, providing long-term remission in a significant proportion of patients. Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs. (Source: Acta Neurologica Belgica)
Source: Acta Neurologica Belgica - April 15, 2024 Category: Neurology Source Type: research
Synthesis, radiosynthesis and biochemical evaluation of fluorinated analogues of sphingosine-1-phosphate receptor 3 specific antagonists using PET
Bioorg Med Chem. 2024 Mar 26;104:117697. doi: 10.1016/j.bmc.2024.117697. Online ahead of print.ABSTRACTSphingosine-1-phosphate and its receptors (S1PRs) are involved in several diseases such as auto immunity, inflammation and cardiovascular disorders. The S1P analogue fingolimod (Gilenya®) is currently in use for the treatment of relapsing multiple sclerosis. S1PRs are also promising targets for clinical molecular imaging in vivo. The organ distribution of individual S1PRs can be potentially achieved by using S1PR subtype-specific (radiolabeled) chemical probes. Here, we report our efforts on synthesis and in vivo potency...
Source: Bioorganic and Medicinal Chemistry - April 10, 2024 Category: Chemistry Authors: Vysakh Puspha Prasad Stefan Wagner Petra Keul Sven Hermann Bodo Levkau Michael Sch äfers G ünter Haufe Source Type: research
Synthesis, radiosynthesis and biochemical evaluation of fluorinated analogues of sphingosine-1-phosphate receptor 3 specific antagonists using PET
Bioorg Med Chem. 2024 Mar 26;104:117697. doi: 10.1016/j.bmc.2024.117697. Online ahead of print.ABSTRACTSphingosine-1-phosphate and its receptors (S1PRs) are involved in several diseases such as auto immunity, inflammation and cardiovascular disorders. The S1P analogue fingolimod (Gilenya®) is currently in use for the treatment of relapsing multiple sclerosis. S1PRs are also promising targets for clinical molecular imaging in vivo. The organ distribution of individual S1PRs can be potentially achieved by using S1PR subtype-specific (radiolabeled) chemical probes. Here, we report our efforts on synthesis and in vivo potency...
Source: Bioorganic and Medicinal Chemistry - April 10, 2024 Category: Chemistry Authors: Vysakh Puspha Prasad Stefan Wagner Petra Keul Sven Hermann Bodo Levkau Michael Sch äfers G ünter Haufe Source Type: research
Synthesis, radiosynthesis and biochemical evaluation of fluorinated analogues of sphingosine-1-phosphate receptor 3 specific antagonists using PET
Bioorg Med Chem. 2024 Mar 26;104:117697. doi: 10.1016/j.bmc.2024.117697. Online ahead of print.ABSTRACTSphingosine-1-phosphate and its receptors (S1PRs) are involved in several diseases such as auto immunity, inflammation and cardiovascular disorders. The S1P analogue fingolimod (Gilenya®) is currently in use for the treatment of relapsing multiple sclerosis. S1PRs are also promising targets for clinical molecular imaging in vivo. The organ distribution of individual S1PRs can be potentially achieved by using S1PR subtype-specific (radiolabeled) chemical probes. Here, we report our efforts on synthesis and in vivo potency...
Source: Bioorganic and Medicinal Chemistry - April 10, 2024 Category: Chemistry Authors: Vysakh Puspha Prasad Stefan Wagner Petra Keul Sven Hermann Bodo Levkau Michael Sch äfers G ünter Haufe Source Type: research
The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta ‑Analysis
Conclusions: The results of this systematic review show that efficacy of interferon and fingolimod in controlling relapse rate and disability is similar.International Journal of Preventive Medicine 14():131, December 2023. | DOI: 10.4103/ijpvm.ijpvm_12_22 Corresponding Author: Dr. Mahsa GhajarzadehE ‑mail: m.ghajarzadeh@gmail.comYou can also search for this author in:PubMed Google Scholar (Source: International Journal of Preventive Medicine)
Source: International Journal of Preventive Medicine - April 8, 2024 Category: International Medicine & Public Health Source Type: research
Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail
ConclusionThe present study revealed a positive short-term effect of extended-release fampridine on MFIS in PwMS. However, this effect was not significantly superior to the placebo. (Source: Acta Neurologica Belgica)
Source: Acta Neurologica Belgica - April 6, 2024 Category: Neurology Source Type: research
Comparative efficacy of ofatumumab < em > versus < /em > oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons
CONCLUSION: Complementary ITC methods showed ofatumumab was superior to cladribine, fingolimod, and ozanimod in lowering relapse rates and delaying disability progression among patients with RMS. Our study supports the therapeutic superiority of mAbs over currently available oral DMTs for RMS and the delineation of mAbs as high-efficacy therapies.PMID:38525490 | PMC:PMC10960976 | DOI:10.1177/17562864241239453 (Source: Adv Data)
Source: Adv Data - March 25, 2024 Category: Epidemiology Authors: Nicholas Riley Christopher Drudge Morag Nelson Anja Haltner Michael Barnett Simon Broadley Helmut Butzkueven Pamela McCombe Anneke Van der Walt Erin O Y Wong Martin Merschhemke Nicholas Adlard Rob Walker Imtiaz A Samjoo Source Type: research
Comparative efficacy of ofatumumab < em > versus < /em > oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons
CONCLUSION: Complementary ITC methods showed ofatumumab was superior to cladribine, fingolimod, and ozanimod in lowering relapse rates and delaying disability progression among patients with RMS. Our study supports the therapeutic superiority of mAbs over currently available oral DMTs for RMS and the delineation of mAbs as high-efficacy therapies.PMID:38525490 | PMC:PMC10960976 | DOI:10.1177/17562864241239453 (Source: Adv Data)
Source: Adv Data - March 25, 2024 Category: Epidemiology Authors: Nicholas Riley Christopher Drudge Morag Nelson Anja Haltner Michael Barnett Simon Broadley Helmut Butzkueven Pamela McCombe Anneke Van der Walt Erin O Y Wong Martin Merschhemke Nicholas Adlard Rob Walker Imtiaz A Samjoo Source Type: research
Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework
This study effectively demonstrated the use of an innovative statistical methodology to test a clinical hypothesis using real-world data to perform early target validation for drug discovery. Although there was a trend among patients treated with dimethyl fumarate towards a decreased incidence of type 2 diabet es, cardiovascular disease and chronic kidney disease relative to other disease-modifying therapies–which was statistically significant for the comparison with teriflunomide–this study did not definitively support the hypothesis that Nrf2 activation provided additional metabolic disease benefit in patients with m...
Source: PLoS One - March 22, 2024 Category: Biomedical Science Authors: Alan J. M. Brnabic Source Type: research
Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis
This study comprehensively evaluates the magnitude of the effect of different DMTs on blood immune cells providing a better understanding of therapy outcome. Furthermore, the lack of a discernible pattern in the effects of DMTs on blood immune cells suggests that multiple immune cells can independently modulate the disease.PMID:38461632 | DOI:10.1016/j.intimp.2024.111826 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 10, 2024 Category: Allergy & Immunology Authors: Jo ão Canto-Gomes Daniela Boleixa Catarina Teixeira Ana Martins da Silva In és González-Suárez Jo ão Cerqueira Margarida Correia-Neves Claudia Nobrega Source Type: research
Fingolimod improves diffuse brain injury by promoting AQP4 polarization and functional recovery of the glymphatic system
CONCLUSIONS: In brief, these findings suggest that fingolimod alleviates whole-brain inflammation and GS system damage after DBI and that inhibiting the GS could weaken the positive effect of fingolimod on nerve function in rats with DBI. Thus, inhibiting inflammation and regulating the GS may be critical for the therapeutic effect of fingolimod on DBI.PMID:38459666 | DOI:10.1111/cns.14669 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - March 9, 2024 Category: Neuroscience Authors: Dongyi Feng Tao Liu Xinjie Zhang Tangtang Xiang Wanqiang Su Wei Quan Rongcai Jiang Source Type: research
Fingolimod improves diffuse brain injury by promoting AQP4 polarization and functional recovery of the glymphatic system
CONCLUSIONS: In brief, these findings suggest that fingolimod alleviates whole-brain inflammation and GS system damage after DBI and that inhibiting the GS could weaken the positive effect of fingolimod on nerve function in rats with DBI. Thus, inhibiting inflammation and regulating the GS may be critical for the therapeutic effect of fingolimod on DBI.PMID:38459666 | PMC:PMC10924110 | DOI:10.1111/cns.14669 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - March 9, 2024 Category: Neuroscience Authors: Dongyi Feng Tao Liu Xinjie Zhang Tangtang Xiang Wanqiang Su Wei Quan Rongcai Jiang Source Type: research
Early intensive versus escalation treatment in patients with relapsing –remitting multiple sclerosis in Austria
ConclusionsESC treatment after DMF and TERI revealed a higher relapse and EDSS progression probability compared to EIT in Austrian RRMS patients. Therefore, an early intensive treatment should be started in patients with an active or highly active disease course. (Source: Journal of Neurology)
Source: Journal of Neurology - March 2, 2024 Category: Neurology Source Type: research
